Winslow Evans & Crocker’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Winslow Evans & Crocker’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20	Closed	-$328	–	1181
2018 Q1	$328	Hold	20	–	–	﹤0.01%	1108
2017 Q4	$418	Sell	20 -96	-83%	-$3.09K	﹤0.01%	1104
2017 Q3	$4.75K	Hold	116	–	–	﹤0.01%	939
2017 Q2	$3.49K	Sell	116 -4	-3%	-$125	﹤0.01%	1109
2017 Q1	$4.34K	Buy	120 +6	+5%	+$264	﹤0.01%	1049
2016 Q4	$5.66K	Sell	114 -6	-5%	-$315	﹤0.01%	1016
2016 Q3	$6.25K	Buy	120 +10	+9%	+$478	﹤0.01%	1011
2016 Q2	$4.51K	Buy	+110	New	+$4.79K	﹤0.01%	1056

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Winslow Evans & Crocker's FPRX Position: Q2 2018 in Review

Winslow Evans & Crocker sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2018, closing a stake of 20 shares — an estimated $328 sold.

Winslow Evans & Crocker first reported a position in FPRX in Q2 2016 and held it in 8 quarters. The position peaked at $6.25K in Q3 2016. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2018.

Winslow Evans & Crocker reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Winslow Evans & Crocker sold 20 Five Prime Therapeutics, Inc. shares in Q2 2018, an estimated $328.
Winslow Evans & Crocker first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 8 quarters.
Winslow Evans & Crocker's Five Prime Therapeutics, Inc. position peaked at $6.25K in Q3 2016.
123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2018.

Based on Winslow Evans & Crocker's 13F filing for Q2 2018, filed 17 Jul 2018.